Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Sees New OTC Drug Law Spurring ‘Switch’ Production

This article was originally published in PharmAsia News

Executive Summary

The effort by Japan's Ministry of Health to encourage more production of over-the-counter "switch drugs" appears to be bearing fruit. Drug makers are racing to release their versions of the drugs and help revive the OTC market in Japan. New laws take effect next June that classify OTC drugs into three groups based on their efficacy and risk of side effects. The "switch drugs" would require a pharmacist to explain how the drugs for lifestyle ailments are to be used. That provision is expected to eliminate pharmacy competition by most discount retailers, so manufacturers are focusing first on that sector of medicines. (Click here for more - a subscription may be required

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel